@aliullah7760: #foryoupage❤️❤️ #fyp #tiktok #پشتون_تاجیک_هزاره_ازبک_زنده_باد🇦🇫 #unfrezzmyaccount

AK writer
AK writer
Open In TikTok:
Region: PK
Friday 21 August 2026 18:42:08 GMT
13912
939
85
193

Music

Download

Comments

ayazkhan24380
ayazkhan :
nice very nice
2026-08-26 04:57:39
0
m.azhar4020
M Azhar :
bbbbbbbbbbbbbnb🥰🥰🥰🥰
2026-08-26 12:33:44
0
sadajanan544
💔SADA janan💔 :
Love♥️♥️♥️
2026-08-27 03:23:39
0
mohammad30592
karachi king :
please T bana do please
2026-08-21 18:52:45
1
user5309266193818
khan :
S♥️S
2026-08-26 07:57:38
0
kalim1657
user19940157988 :
2026-08-22 14:34:46
2
bismillahjan.bk
Bismillahjan BK :
BBBBBBBB Bismillah jan BK💔
2026-08-25 17:30:17
0
shaheen.shah938
Quetta chai parata☕☕ :
pls aik video meri laeiiii banoooo S ....B
2026-08-22 11:58:21
0
saidqahir33
said qahir :
Amin
2026-08-22 10:14:13
0
kalim1657
user19940157988 :
2026-08-22 14:34:14
1
ns_354_b
NS PATHAN :
N ❤️S
2026-08-21 22:17:58
1
khan5543845858
QURASHI KHATTAK ☠️🔫 :
bro plz sF ❤️
2026-08-21 19:02:13
1
user6295591071747
user03708082378 :
BS🥰
2026-08-26 04:46:58
0
sahil.hadare
Sahil Hadare :
🥰🥰🥰
2026-08-21 18:55:08
1
kashif.buneri6
Kashif buneri :
😭😭😭
2026-08-21 19:16:43
1
zabee.khan65
Agha Sab :
🥰🥰🥰
2026-08-21 18:56:03
1
malik3029524
🔥ذہنی مریض💔 :
💕💕💕
2026-08-21 19:16:44
1
basharatali8736
basharat 🇸🇦🇸🇦🇸🇦🇸🇦🇸🇦 :
🥰🥰🥰
2026-08-26 17:56:11
0
user1469582400416
هجران کاموال :
🥰🥰🥰
2026-08-27 04:01:44
0
user092678031
❤️‍🔥ᴹᴿ ᭄☞BILAL.࿐MOHMAND🔥 :
♥️♥️♥️
2026-08-21 18:46:28
1
wasambaloch33
wasam Baloch B :
♥️♥️♥️
2026-08-27 01:44:08
0
nimat.tanha1
Nimat Tanha :
💔💔💔
2026-08-26 17:56:58
0
magar.kaxa79o
magar kanxa 👑🇳🇵💟 :
😁😁😁
2026-08-22 01:36:49
1
dr....zazai
Bilalzazai :
🥰🥰🥰
2026-08-26 17:29:09
0
pashton.zalmi0
Pashton Zalmi :
💖💖💖
2026-08-27 03:19:22
0
To see more videos from user @aliullah7760, please go to the Tikwm homepage.

Other Videos

on august 19 2026 moderna and merck announced the first successful late-stage results for a personalized mrna cancer vaccine. the vaccine is called intismeran (also known as intismeran autogene or previously mrna-4157/v940). it was tested in combination with merck’s immunotherapy drug keytruda in a phase 3 trial involving 1137 patients with high-risk stage iib to iv melanoma whose tumors had already been surgically removed. the trial met both its main goal of improving recurrence-free survival and a key secondary goal of improving distant metastasis-free survival. in plain terms the vaccine plus keytruda made it less likely for the melanoma to come back or spread to other parts of the body compared with keytruda alone. this is the first time a personalized neoantigen mrna cancer vaccine has succeeded in a large randomized phase 3 study. how it works: doctors sequence the patient’s tumor, identify unique mutations called neoantigens (up to 34 of them), and then use mrna technology to create a custom vaccine that teaches the immune system to recognize and attack those specific cancer markers. the whole manufacturing process takes roughly six weeks. earlier smaller trials had already shown roughly a 49 percent reduction in the risk of recurrence or death and a 59 percent reduction in the risk of distant spread or death over five years. the companies have not released the full detailed numbers yet but plan to present them at an upcoming medical conference. they are already talking with regulators about possible approval. some reports suggest the treatment could reach patients as early as next year if everything moves quickly. several sources also note that ai tools helped with selecting the best neoantigen targets for each patient. #larpochka #techtok #llm #machinelearning #claude
on august 19 2026 moderna and merck announced the first successful late-stage results for a personalized mrna cancer vaccine. the vaccine is called intismeran (also known as intismeran autogene or previously mrna-4157/v940). it was tested in combination with merck’s immunotherapy drug keytruda in a phase 3 trial involving 1137 patients with high-risk stage iib to iv melanoma whose tumors had already been surgically removed. the trial met both its main goal of improving recurrence-free survival and a key secondary goal of improving distant metastasis-free survival. in plain terms the vaccine plus keytruda made it less likely for the melanoma to come back or spread to other parts of the body compared with keytruda alone. this is the first time a personalized neoantigen mrna cancer vaccine has succeeded in a large randomized phase 3 study. how it works: doctors sequence the patient’s tumor, identify unique mutations called neoantigens (up to 34 of them), and then use mrna technology to create a custom vaccine that teaches the immune system to recognize and attack those specific cancer markers. the whole manufacturing process takes roughly six weeks. earlier smaller trials had already shown roughly a 49 percent reduction in the risk of recurrence or death and a 59 percent reduction in the risk of distant spread or death over five years. the companies have not released the full detailed numbers yet but plan to present them at an upcoming medical conference. they are already talking with regulators about possible approval. some reports suggest the treatment could reach patients as early as next year if everything moves quickly. several sources also note that ai tools helped with selecting the best neoantigen targets for each patient. #larpochka #techtok #llm #machinelearning #claude

About